what's trending

5 most popular innovation stories in Houston this week

InnovationMap named its inaugural awards judges, innovators to know, and more are this week's trending stories. Courtesy photos

Editor's note:Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included innovators to know, a Q&A with an innovative pharmaceuticals founder, news of a major leadership change, and more.

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Ryan Sitton of Pinnacle, Julia P. Clarke of Raba Kistner Inc., and Phillip Yates of Equiliberty. Courtesy photos

In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from data analysis to fintech — recently making headlines in Houston innovation. Click here to continue reading.

InnovationMap names judges for inaugural awards program

Here's who's making the call for the inaugural InnovationMap Awards. Graphic via Gow Media

It's been two weeks since InnovationMap announced its inaugural awards program presented by Techwave — and the ecosystem is already buzzing with excitement to find out the top innovative companies in town.

The InnovationMap Awards will honor Houston's innovators and their breakthrough technologies across industries. The program and hybrid event — which will take place September 8 — will shine a spotlight on the movers and shakers within Houston's burgeoning innovation community. Nominations are open for the awards now — and the deadline to submit your nomination is July 23. Click here to continue reading.

Exclusive: New accelerator launches to prepare Houston's future civic leaders

HTXelerator, which is launching in September, is aimed at supporting future leaders and connecting them with the city's burgeoning tech scene. Photo via HoustonTX.gov

A new nonprofit program dedicated to preparing the future leaders of the city of Houston's is launching with the city's burgeoning innovation ecosystem in mind.

HTXelerator is a three-month program that trains its group of aspiring politicians on the nuts and bolts of city government. The program — designed to be similar to a tech accelerator — will launch out of The Cannon Downtown and The Ion in September. The idea to link the program with the startup and innovation community is intentional, says Randy Romman, executive director. Co-located with The Cannon and The Ion, Romman says he hopes the accelerator provides an opportunity for collisions between politics and innovation.

"Houston, in particular, needs more tech dollars and more people aware of tech dollars," he tells InnovationMap. "That's why we wanted this in The Cannon and The Ion — so that those people can sit in on these classes and participate. Our topics range from land use to economic development, transportation, and more. And hopefully these future leaders can learn something from the tech world." Click here to continue reading.

Houston founder talks growth and innovation in the pharmaceuticals industry

Shaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

When Shaun Noorian encountered what he felt was a poorly ran process, as an engineer, he built something better. Now, he runs one of the nation's largest compounding pharmacies that's at a pivotal time for growth.

Headquartered in Houston, Empower Pharmacy is opening two new facilities locally — one debuts later this year and the other in 2022. Ahead of this milestone for his company, Noorian joined InnovationMap for a Q&A about how he decided to start his company and how he's grown it from a small office to two 85,000-square-foot facilities — as well as how Houston has been a big part of his company's success. Click here to continue reading.

Houston Exponential leader resigns, interim named

Harvin Moore has resigned from his position as president of Houston Exponential. Serafina Lalany is acting as interim while a committee identifies the organization's new leader. Photos courtesy of HX

Houston Exponential has announced a leadership change, according to a statement from the organization.

Harvin Moore, who has served as president of HX since June 2019, has announced his resignation to the chair of the organization, Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures. In the statement, Burger says Moore is resigning to devote more time to working with growth-stage companies as a mentor, adviser, and investor.

Serafina Lalany, vice president of operations at HX, will act as interim executive director. Click here to continue reading.

Trending News

 
 

Promoted

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Trending News

 
 

Promoted